„This is a randomised, phase III, non-inferiority trial evaluating radiation therapy (RT) versus observation (no RT) following breast conserving surgery in patients who are planned to receive adjuvant endocrine therapy for stage I breast cancer of luminal A subtype and Risk of Recurrence (ROR) score ≤60 characterised using Prosigna (PAM50) Assay.”

    Lead Trial Coordinator
    Holly Shaw

    Trial Coordinator
    Meredith Kissel

    IBCSG Data Management Center/FSTRF
    4033 Maple Road
    Amherst, New York 14226 USA
    Phone: +1 716 834 0900
    Fax: +1 716 833 3990
    Email:

    This email address is being protected from spambots. You need JavaScript enabled to view it.

     

    Targeted Accrual
    1170

    International Breast
    Cancer Study Group

    Effingerstrasse 40
    3008 Bern, Switzerland

    Contact
    Phone: +41 31 511 94 00
    E-mail: ibcsgcc@ibcsg.org

    Member Login